Although further experimental study will be needed to prove our results, the genetic polymorphism of ADAM17 and serum bilirubin level might be used as a potential marker for estimating the risk of allergic diseases and can provide new guidelines for the management of the allergic march. This evidence concerns the gene ADAM17 and allergic disease.